RxDoctor Payments Data

Kevin Martinolich, MD

Sleep Medicine · Knoxville, TNNPI 1659388197

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,520 of the $8,653 with a category attached, or 63.8%. 15 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 32.9% of the total. Reporting peaked in 2023 at $4,430 and has fallen 96.1% since, to $172 in 2025.

$8,653in general payments, 2019–2025

Across 151 payments — averaging $57.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$3K
  • ZOLL Respicardia, Inc.$2K
  • Jazz Pharmaceuticals Inc.$2K
  • Axsome Therapeutics, Inc.$683
  • Harmony Biosciences LLC$378
  • Avadel CNS Pharmaceuticals, LLC$324
  • plus $633 from 9 others

What the payments were for

  • Travel & lodging$2,78632%
  • Food & beverage$5,52064%
  • Education$3474%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,653 in reported general payments places this provider in the 85th percentile of 41 sleep medicine providers in Tennessee.

See all sleep medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$61,558
Medicare patients
554
Services billed
800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XyremSodium Oxybate20$275,504
LumryzSodium Oxybate13$241,692
WakixPitolisant Hcl24$176,977
SunosiSolriamfetol Hcl30$28,974
NeuproRotigotine15$20,929
BelsomraSuvorexant39$15,643
Modafinil66$9,975
Atomoxetine Hcl25$2,715
SymbicortBudesonide/Formoterol Fumarate12$2,599
Armodafinil40$2,309
Gabapentin195$2,215
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine35$1,664
Temazepam15$1,316
Ramelteon12$1,310
Trazodone Hcl75$740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avadel CNS Pharmaceuticals, LLCLumryz$324$241,69213 claims
Harmony Biosciences LLCWakix$378$176,97724 claims
Axsome Therapeutics, Inc.Sunosi$683$28,97430 claims
UCB, Inc.Neupro$24$20,92915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 41 sleep medicine providers in Tennessee.

Other sleep medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →